FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 822 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as... April 14, 2023 The Appraisal – Does a charity have a role in biotech... August 17, 2023 FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma October 27, 2025 Steps towards a smokefree society August 31, 2022 Load more HOT NEWS Can Getting a Tattoo Cause Cancer? New Areolar Incision Technique Leaves Almost No Scars for Breast Cancer... HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy
